Introduction
============

The increasing use of massive parallel sequencing of customized multi-gene panels, for germline clinical testing of hereditary breast and ovarian cancer (HBOC) and Lynch syndrome, is leading to higher detection of genetic variants of unknown significance (VUS).

All exonic or intronic VUS can be potentially spliceogenic by disrupting the *cis* DNA sequences that define exons, introns, and regulatory sequences necessary for a correct RNA splicing process. Specifically, the *cis* DNA elements include: (i) exon--intron boundary core consensus nucleotides (GT at +1 and +2 of the 5′donor site and AG at -1 and -2 of the 3′acceptor site); (ii) intronic and exonic nucleotides adjacent to these invariable nucleotides that are also highly conserved and have been found to be critical for splice site selection: CAG/**GU**AAGU in donor sites and NY**AG**/G in acceptor sites; (iii) branch point and polypyrimidine tract sequence motifs, essential for the spliceosome complex formation; (iv) intronic and exonic sequences that act as splicing enhancers (ISE and ESE) or silencers (ISS and ESS), regulatory motifs that are usually bound by serine/arginine (SR)-rich proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs), respectively ([@B2]; [@B24]; [@B1]). A nucleotide change in any of these elements could lead to incorrect splice site recognition, creating new ones or activating the cryptic ones, resulting in aberrant transcripts and in non-functional proteins associated with disease such as hereditary cancer.

Interestingly, it has recently been described that hereditary cancer genes (including some HBOC and Lynch genes) are enriched for spliceogenic variants ([@B21]). This finding highlights the importance of both the identification and the functional interpretation of variants causing RNA alterations in hereditary cancer genes. In HBOC syndrome and Lynch Syndrome, the clinical classification of VUS is essential since carriers of pathogenic variants may benefit from cancer prevention and risk-reducing strategies, make informed decisions about prophylactic surgery, and benefit from targeted treatments ([@B18]). Conversely, carriers of non-pathogenic variants can be excluded from intensive follow-ups and avoid unnecessary risk-reducing surgery ([@B8]).

To detect splice site alterations, *in vitro* splicing assays with patient's RNA or minigenes are widely used. However, testing all variants detected in the vicinity of exon--intron boundaries can be time consuming and expensive. In consequence, to select variants to be experimentally evaluated, a large number of prediction programs have been developed. These splicing computational tools are based on different premises. The most commonly used are based on Position Weight Matrix (PWM), in which each nucleotide on the splice site sequence is scored and ranked based on its frequency from its aligned consensus sequence ([@B23]; [@B6]). Neural network programs use sets of sequences from databases to identify splicing sites ([@B20]). Tools based on Maximum Entropy Distribution models take into account the dependencies between nucleotide positions ([@B31]). Approaches like SPANR ([@B30]) use DNA and RNA sequence information and a machine learning method, to predict splicing alterations, enabling the identification of variants affecting *cis* and *trans* splicing factors. Another type of splicing tool has been developed using ensemble learning methods (adaptive boosting and random forest) taking advantage of individual computational tools ([@B13]).

Several studies have analyzed the performance of these tools for genes related to cancer and other diseases and report discordant results without a consensus guideline recommending which programs should be used ([@B12], [@B11]; [@B10]; [@B28]; [@B5]; [@B26]; [@B4]; [@B13]; [@B25]) (**Table [1](#T1){ref-type="table"}**). Here, we present an evaluation of the performance of commonly used splicing *in silico* tools, comparing their output with the experimental evidences obtained by RNA *in vitro* analysis of variants detected in HBOC and Lynch syndrome genes. In the first phase of the study, we assessed the accuracy of the splicing *in silico* tools with a dataset of RNA *in vitro* outcomes collected from four Spanish cancer genetic units. Subsequently, we validated the best algorithms obtained in the discovery phase, with findings obtained after RNA analysis extracted from different curated databases and reported literature.

###### 

Publications evaluating *in silico* splicing site tools.

  Reference   Number of variants   Source of the variants and *in vitro* data                                            Gene(s)         Region analyzed                                Experimental design                                                          Prediction tools evaluated                                                                   Accuracy of recommended tools                                                                                                                                                                     Consensus guideline
  ----------- -------------------- ------------------------------------------------------------------------------------- --------------- ---------------------------------------------- ---------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B12]      39                   ^∗^Experimental evidence                                                              *RB1*           ±60 nucleotides from an AG/GT site             One evaluation stage                                                         NNSplice, PWM, MES, ASSA, ESEfinder, RESCUE-ESE                                              NA                                                                                                                                                                                                Not specifically provided
  [@B10]      18                   Experimental evidence                                                                 *LDLR*          Intronic: 5′ until +5. 3′ until -16            One evaluation stage                                                         MES, NNSplice, NetGene2                                                                      NA                                                                                                                                                                                                Not specifically provided
  [@B28]      29                   Experimental evidence                                                                 *BRCA1/BRCA2*   Intronic: 5' until +60. 3' until -20           One evaluation stage                                                         NNSplice, NetGene2, PWM, ASSA, MES, HSF                                                      NA                                                                                                                                                                                                Not specifically provided
  [@B5]       623                  UMD locus-specific databases, HGMD, and datasets from previous studies                Multiple        Not specifically stated                        One evaluation stage                                                         GENSCAN, GeneSplicer, HSF, MES, NNSplice, SplicePort, SplicePredictor, SpliceView, SROOGLE   Invariable position: HSF, MES, SpliceView and SROOGLE 100%. Intronic SS +3, +5 and last exonic position: MES 100%. Other SS intronic position: MES and SplicePort 5' 76/68% and 3' 77.27/77.27%   Invariable position: HSF, MES, SpliceView and SROOGLE. Intronic SS +3, +5 and last exonic position: MES. Other SS intronic positions: MES and SplicePort
  [@B26]      53                   Experimental evidence                                                                 *BRCA1/BRCA2*   Not specifically stated                        One evaluation stage                                                         PWM, GeneSplicer, NNSplice, MES, HSF                                                         NA                                                                                                                                                                                                Not specifically provided
  [@B11]      272                  Experimental evidence                                                                 *BRCA1/BRCA2*   Not specifically stated                        One evaluation stage                                                         NNSplice, SSF, MES, ESEfinder, RESCUE-ESE, HSF                                               Accuracy as AUC: MES: 0.956, SSF-like: 0.914                                                                                                                                                      Sequential MES and SSF
  [@B4]       24                   Experimental evidence                                                                 *BRCA1/BRCA2*   Not specifically stated                        One evaluation stage                                                         PWM, MES, NNSplice, GeneSplicer, HSF, NetGene2, SpliceView, SplicePredictor, ASSA            NA                                                                                                                                                                                                HSF and ASSA
  [@B14]      2,959                HGMD, SpliceDisease database and DBASS. Negative variants from 1000 Genomes Phase 1   Multiple        5': from -3 to +8. 3': from -12 to +2          Evaluation of individual tools + new model construction + validation stage   SSF-like, MES, NNSplice, GeneSplicer, HSF, NetGene2, GENSCAN, SplicePredictor, ^∗∗^dbscSNV   SSF-like: 91.1% MES: 89.5%/dbscSNV: 93.3%                                                                                                                                                         SSF-like, MES/dbscSNV
  [@B25]      272                  HGMD (damaging variants) and negative variants from 1000 Genomes Phase 1              Multiple        Intronic: 5' from +3 to +7. 3' from -3 to -9   One evaluation stage                                                         HSF, MES, NNSplice, ASSP                                                                     Accuracy as AUC: MES: 0.878 ASSP: 0.881 HSF: 0.834                                                                                                                                                MES, ASSP, and HSF combination
  [@B16]      395                  Experimental evidence                                                                 Multiple        5': from -3 to +8. 3': from -12 to +2          Training + evaluation stage                                                  HSF, MES, SSF-like, NNSplice, GS, SPiCE (MES and SSF combination)                            SPiCE 95.6%                                                                                                                                                                                       SPiCE (Th~Se~ threshold with MES and SSF combination)

∗

Experimental evidence: experimental

in vitro

RNA results collected specifically for the study, derived from either patient blood cells or minigene assay.

∗∗

dbscSNV: database containing the adaptive boosting and random forests scores. UMD, Universal Mutation Database; HGMD, the Human Gene Mutation Database; DBASS, Aberrant Splice Database; Splice NNSplice, Site Prediction by Neural Network; PWM, Position Weight Matrix; MES, MaxEntScan; ASSA, Automated Splice-Sites Analyses; HSF, Human Splice Finder; SSF, Splice Site Finder; GS, GeneSplicer; SROOGLE, splicing regulation online graphical engine; ASSP, Alternative Splice Site Predictor; NA, information not available in the paper; SS, splicing site; AUC, area under the curve; Th

Se

, optimal sensitivity threshold.

Materials and Methods {#s1}
=====================

Variant Selection
-----------------

### Discovery Set

We restricted the study to variants located within the last 10 exonic and 20 first intronic nucleotides from the 5′ splice donor site, and the last 20 intronic and the first 10 exonic nucleotides from the 3′ splice acceptor site (-10 to +20 and -20 to +10, respectively). *BRCA1, BRCA2, MLH1, MSH2, MSH6*, and *PMS2* variants were selected from HBOC and Lynch syndrome patients routinely analyzed for diagnostic purposes. We also included *ATM, BRIP1, CDH1, PALB2, PTEN, RAD51D, STK11*, and *TP53* variants obtained in a research series of *BRCA1* and *BRCA2* negative HBOC patients. Genetic variants with unequivocal experimental evidences showing presence or absence of alterations in the mRNA, were collected from four different Spanish centers: Hospital Universitari Vall d'Hebron (HUVH), Barcelona; Hospital Clínico San Carlos (HCSC) Madrid; Fundación Pública Galega de Medicina Xenomica (FPGMX), Santiago de Compostela; Institut Català d'Oncologia (ICO), Hospital Duran i Reynals, Barcelona.

The variants included in the discovery set were analyzed *in vitro* in carriers and controls. RNA was isolated from whole blood leukocytes or short-term lymphocyte cultures, phytohaemagglutinin stimulated, and treated with and without puromycin. The contributing laboratories used diverse isolation protocols and/or cDNA synthesis strategies following ENIGMA recommendations ([@B3]; [@B29]). Briefly, the splicing products generated by reverse transcription-polymerase chain reaction (RT-PCR) assays were characterized using agarose gel or capillary electrophoresis in a QIAxcel instrument with QIAxcel DNA High Resolution Kit (QIAGEN) or an Agilent 2100 Bioanalyzer (Agilent), and Sanger sequencing. PCR primers were designed to amplify at least one whole exon 5′ and 3′ flanking the exon harboring the variant of interest. Primer sequences are available upon request.

The study was approved by the Institutional Review Board of each participating center. Patients received genetic counseling and written informed consent was obtained for further genetic and research studies.

### Validation Set

At this stage, the predictors that presented the best performance alone or in combination, were applied to compare their predictions with the *in vitro* RNA results from the dataset obtained through literature and databases. We chose a collection of variants reported in INSIGHT, ClinVar and published works that were (i) located within the regions defined for the discovery set; (ii) identified in the set of cancer risk genes included above; (iii) experimentally confirmed as spliceogenic and non-spliceogenic in blood samples or with minigene assay at least by RT-PCR, agarose gel and Sanger Sequencing analysis; and (iv) not located at exonic splicing enhancer (ESE) regions with specific experimental evidence of causing splicing alteration.

*In silico* Splice Tools
------------------------

A total of six splice-site prediction software programs were selected for this study. Two ensemble prediction scores constructed by [@B13] using adaptive boosting and random forests ensemble learning methods, were extracted from dbscSNV database^[1](#fn01){ref-type="fn"}^. Splicing-based Analysis of Variants (SPANR), a computational model of splicing derived from the application of "deep learning" computer algorithms ([@B30]) was ascertained by its own web site^[2](#fn02){ref-type="fn"}^. Splice Site Finder (SSF-like) (based on [@B23]), MaxEntScan (MES) ([@B31]), Splice Site Prediction by Neural Network (NNPLICE) ([@B20]), and Human Splicing Finder (HSF) ([@B6]) accessed through Alamut Visual 2.10 (Interactive Biosoftware). The GeneSplicer program is also included in the splicing module of Alamut, but it was excluded from the study since we noticed it had an exceedingly high missing scores (no estimation was obtained for 30% of the variants analyzed; data not shown), which had also been reported by [@B13]. SPANR and dbscSNV do not analyze insertions and deletions and dbscSNV gives estimations for variants only located from -3 to +8 at 5′ and -12 to +2 at 3′ (**Supplementary Table [1](#SM1){ref-type="supplementary-material"}**).

To interrogate the splicing prediction tools, we calculated the score variation caused by the variant in the donor site or acceptor site. To do that, we compared the score computed in the wild-type sequence (WT) to the score computed in the variant sequence (VAR) as:
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We calculated the % score variation for four out of the six tools (SSF-like, HSF, MES, and NNSPLICE), since dbscSNV and SPANR already provide a score change.

To consider a % score change as a positive prediction of a splicing motif disruption caused by the variant, which would lead to aberrant splicing, we adopted thresholds pre-established in the literature (**Supplementary Table [1](#SM1){ref-type="supplementary-material"}**). When two programs were combined, a correct prediction of splicing alteration was considered if at least one of them scored above the threshold. When three, four, five, or six programs were combined, all tools but one had to score above the threshold to indicate splicing alteration.

Performance Assessment
----------------------

In the discovery and validation phases, the experimental RNA results for each collected variant were annotated as positive splicing alteration when they unequivocally, verified by gel electrophoresis and Sanger sequencing, lead to: exon skipping, use of a new or cryptic splice site or altered alternative transcript profile. In contrast, a negative splicing alteration was annotated when the *in vitro* RNA result was exactly the same as that obtained in control samples.

For both stages, we calculated the overall accuracy (ratio of overall correct predictions to the total number of predictions), specificity (correct identification of non-spliceogenic variants; true negative rate), and sensitivity (correct identification of deleterious variants; true positive rate). The positive predictive values (PPV, proportion of positive predictions that were true positives), negative predictive values (NPV, proportion of negative predictions that were true negatives), false negative rates (FNR, proportion of false negative detection), and false positive rates (FPR, proportion of false positive detection) were also calculated. Matthews correlation coefficient (MCC) was used to provide a balanced comparison between *in silico* tools.

Results
=======

Discovery Set
-------------

A total of 99 variants with unequivocal RNA *in vitro* results were studied, located within positions -10 to +20 from the 5′ donor site, and within -20 to +10 from the 3′ acceptor site (**Supplementary Table [2](#SM1){ref-type="supplementary-material"}**). Forty-four of the 99 variants generated a splice defect, with 11 and 9 disrupting the canonical GT or AG dinucleotides, respectively. The 24 remaining variants with aberrant splicing were located outside invariable GT or AG positions, with 15 variants altering the 5′ splice site and nine altering the 3′ splice site. Fifty-five variants did not yield an aberrant splicing, all located outside invariant dinucleotides. **Figure [1](#F1){ref-type="fig"}** displays the number of positive and negative splicing results relative to variant location.

![*In vitro* RNA results collected in the **discovery set.** Experimental data are displayed according to variation location. Positive splicing alterations include: exon skipping, use of a new or cryptic splice site or an altered-alternative transcript profile. Negative splicing alteration: *in vitro* RNA result was exactly the same as that obtained in control samples. Spl, splicing.](fgene-09-00366-g001){#F1}

Six *in silico* tools were used to interrogate the 99 variants, and their corresponding % score variation was obtained. These outputs were compared to the experimental RNA results. The respective thresholds pre-established in the literature were adopted for each program (**Supplementary Table [1](#SM1){ref-type="supplementary-material"}**).

**Supplementary Table [2](#SM1){ref-type="supplementary-material"}** lists the % score variation obtained from each splicing tool used to assess the 99 variants, highlighting which scores were in agreement with the RNA analysis outcome. Of note, seven insertions or deletions were not computed by SPANR and dbscSNV, while estimations for 33 substitutions were not provided by dbscSNV.

**Table [2](#T2){ref-type="table"}** shows separately, for 5′ (52 variants), 3′ (47 variants), and both splice sites (global, 99 variants), the results of performance analysis for each one of the tools. The six predictors detected wild type (WT) splice sites in reference sequences for all the genes of interest.

###### 

Performance of the individual *in silico* tools in the discovery dataset.

                           Sensitivity   Specificity   Accuracy     MCC         Positive Predictive Value   Negative Predictive Value   False Negative Rate   False Positive Rate   False Discovery Rate   False Omission Rate
  ------------------------ ------------- ------------- ------------ ----------- --------------------------- --------------------------- --------------------- --------------------- ---------------------- ---------------------
  **Donor (5′)**                                                                                                                                                                                           
  **HSF**                  **100.000**   96.154        **98.077**   **0.962**   96.296                      **100.000**                 **0.000**             3.846                 3.704                  **0.000**
  **SSF-like**             96.154        96.154        96.154       0.923       96.154                      96.154                      3.846                 3.846                 3.846                  3.846
  **MES**                  **100.000**   84.615        92.308       0.856       86.667                      **100.000**                 **0.000**             15.385                13.333                 **0.000**
  **dbscSNV**              91.667        90.000        91.176       0.795       95.652                      81.818                      8.333                 10.000                4.348                  18.182
  **NNS**                  92.308        80.769        86.538       0.735       82.759                      91.304                      7.692                 19.231                17.241                 8.696
  **SPANR**                62.500        **100.000**   81.633       0.677       **100.000**                 73.529                      37.500                **0.000**             **0.000**              26.471
  **Acceptor (3′)**                                                                                                                                                                                        
  **SSF-like**             **100.000**   **89.655**    **93.617**   **0.877**   85.714                      **100.000**                 **0.000**             **10.345**            14.286                 **0.000**
  **MES**                  **100.000**   86.207        91.489       0.839       81.818                      **100.000**                 **0.000**             13.793                18.182                 **0.000**
  **dbscSNV**              93.750        77.778        88.000       0.736       **88.235**                  87.500                      6.250                 22.222                **11.765**             12.500
  **HSF**                  83.333        82.759        82.979       0.649       75.000                      88.889                      16.667                17.241                25.000                 11.111
  **NNS**                  88.889        68.966        76.596       0.563       64.000                      90.909                      11.111                31.034                36.000                 9.091
  **SPANR**                41.176        88.460        69.760       0.343       70.000                      69.697                      58.824                11.538                30.000                 30.303
  **Global (5′ and 3′)**                                                                                                                                                                                   
  **SSF-like**             97.727        92.727        **94.949**   **0.900**   91.489                      98.077                      2.273                 7.273                 8.511                  1.923
  **MES**                  **100.000**   85.455        91.919       0.850       84.615                      **100.000**                 **0.000**             14.545                15.385                 **0.000**
  **HSF**                  93.182        89.091        90.909       0.818       87.234                      94.231                      6.818                 10.909                12.766                 5.769
  **dbscSNV**              92.500        84.211        89.831       0.767       **92.500**                  84.211                      7.500                 15.789                **7.500**              15.789
  **NNS**                  90.909        74.545        81.818       0.653       74.074                      91.111                      9.091                 25.455                25.926                 8.889
  **SPANR**                53.659        **94.118**    76.087       0.533       88.000                      71.642                      46.341                **5.882**             12.000                 28.358

Results of the performance evaluation is grouped by donor, acceptor or both splice sites. The best performance scores are highlighted in bold. False Discovery Rate represents the rate of false positives of the total of variants positively predicted and False Omission Rate represents the rate of false negatives of the total negative predicted variants. dbscSNV, database consulted for extracting the adaptive boosting and random forests scores.

On average, predictions for variants located in 5′ regions have higher accuracy (90.98%), sensitivity (90.44%) and specificity (91.28%) compared to those located in 3′ regions (83.74%, 84.52%, and 82.30%, respectively) (**Table [2](#T2){ref-type="table"}**). The predictions computed by HSF (with a score change threshold of -2%) were the most accurate and sensitive for variants at donor site, while for variants at acceptor sites or affecting either acceptor or donor sites (global), SSF-like were the most accurate (with a score change threshold of -5%). MES program (with a score change threshold of -15%) showed 100% of sensitivity on all predictions, but its specificity did not reach 87% in any case. In contrast, SPANR program showed the highest values of specificity for predictions of variants at donor site or all variants affecting either at acceptor or donor splice sites, but the lowest values of sensitivity (**Table [2](#T2){ref-type="table"}**).

Accordingly, the lowest false negative rates for 5′splice site were reached by the HSF and MES predictors, while at 3′splice sites, the SSF-like and MES predictors obtained the lowest false negative rates (**Table [2](#T2){ref-type="table"}** and **Figure [2](#F2){ref-type="fig"}**). In contrast, SPANR predictor had the highest false negative and the lowest false positive rates in almost all cases (**Table [2](#T2){ref-type="table"}** and **Figure [2](#F2){ref-type="fig"}**). Regarding the estimation of the proportion of negative predictions that were true negatives (NPV), HSF or MES and SSF-like or MES achieved the highest values (100%) for donor and acceptor sites, respectively (**Table [2](#T2){ref-type="table"}**).

![False negative and false positive rates for individual splicing prediction tools in the **discovery set**. dbscSNV, database consulted for extracting the adaptive boosting and random forests scores.](fgene-09-00366-g002){#F2}

The accuracy of all possible predictor combinations was further assessed. For 5′ donor splice sites, predictions of HSF alone or HSF together with seven different combinations, SSF-like+SPANR and SSF-like+MES+SPANR reached a 98.08% of accuracy with the highest sensitivity for all the models (100%), obtaining 96.15% of specificity, 0.96 MCC and 100% of NPV (**Supplementary Table [3](#SM1){ref-type="supplementary-material"}**). For 3′ splice sites, a sequential combination recommended by [@B11] using MES as first-line analysis with a cut-off of 15% followed by SSF-like with a 5% threshold achieved the best performance, with a 100% of sensitivity, 96.55% of specificity, 97.87 % of accuracy, 0.96 MCC, and 100% of NPV (**Supplementary Table [4](#SM1){ref-type="supplementary-material"}**). However, SSF-like alone and two more combinations including it also showed a 100% of NPV together with 100% sensitivity and high values of accuracy (for predictions at acceptor site, **Supplementary Table [4](#SM1){ref-type="supplementary-material"}**). Considering the tool combinations for predicting disruption caused by variants located in any of the two splice sites (global), MES and SSF-like sequential combination achieved the best accuracy with a 96.97% and 0.94 of MCC, followed for two combinations, including SSF-like and MES, which showed 100% sensitivity and 100% of NPV (**Supplementary Table [5](#SM1){ref-type="supplementary-material"}**).

Validation Set
--------------

In order to validate the predictors with the best performance obtained in the discovery set, we analyzed a dataset of 346 variants with RNA *in vitro* results published or detailed in free available databases. At donor region, 210 variants were included, 177 showing *in vitro* splicing alterations (65 at intronic GT positions) and 33 showing no splicing effects (all outside intronic GT) (**Figure [3](#F3){ref-type="fig"}** and **Supplementary Table [6](#SM1){ref-type="supplementary-material"}**). One hundred thirty-six variants were located at the acceptor region, 95 showing splicing alterations (67 of them at intronic AG positions), and 41 with absence of alterations (40 of them outside intronic AG) (**Figure [3](#F3){ref-type="fig"}** and **Supplementary Table [7](#SM1){ref-type="supplementary-material"}**). Only SSF-like and SPANR were able to identify all WT splice sites in reference sequences for all the genes of interest.

![*In vitro* RNA results collected in the **validation set.** Experimental data are displayed according to variation location. Variants located at 0 position are those that affect the invariable dinucleotide positions (GT or AG) plus other contiguous nucleotides. Positive splicing alterations include: exon skipping, use of a new or cryptic splice site or an altered-alternative transcript profile. Negative splicing alteration: *in vitro* RNA result was exactly the same as that obtained in control samples. Spl, splicing.](fgene-09-00366-g003){#F3}

We selected for validation, the HSF stand-alone and the combinations HSF+SSF-like and HSF+SSF-like+MES for 5′donor sites (**Supplementary Table [3](#SM1){ref-type="supplementary-material"}**), and the SSF-like alone and the sequential MES and SSF combination for 3′acceptor sites (**Supplementary Table [4](#SM1){ref-type="supplementary-material"}**), considering sensitivity, accuracy, MCC and NPV scores. We excluded the combinations including SPANR or dbscSNV since they do not provide predictions on insertions and deletions.

Overall, the *in silico* predictions in the validation dataset were more accurate for variants with effects on donor splice sites than acceptor sites (**Table [3](#T3){ref-type="table"}** and **Figure [4](#F4){ref-type="fig"}**). These findings were in agreement with those results obtained with the discovery set (**Table [2](#T2){ref-type="table"}**).

###### 

Performance with the validation dataset of the best *in silico* tools previously selected from the results at discovery stage.

                                     Sensitivity   Specificity   Accuracy     MCC         Positive predictive Value   Negative Predictive Value   False Negative Rate   False Positive Rate   False Discovery Rate   False Omission Rate
  ---------------------------------- ------------- ------------- ------------ ----------- --------------------------- --------------------------- --------------------- --------------------- ---------------------- ---------------------
  **[Donor]{.ul}**                                                                                                                                                                                                   
  **HSF**                                                                                                                                                                                                            
  All variants                       96.045        90.909        95.238       0.831       98.266                      81.081                      3.955                 9.091                 1.734                  18.919
  Without invariable dinucleotides   94.643        90.909        93.793       0.830       97.248                      83.333                      5.357                 9.091                 2.752                  16.667
  **HSF+SSF-like**                                                                                                                                                                                                   
  All variants                       **99.435**    **93.939**    **98.571**   **0.946**   **98.876**                  **96.875**                  **0.565**             **6.061**             **1.124**              **3.125**
  Without invariable dinucleotides   **99.107**    **93.939**    **97.931**   **0.941**   **98.230**                  **96.875**                  **0.893**             **6.061**             **1.770**              **3.125**
  **HSF+SSF-like+MES**                                                                                                                                                                                               
  All variants                       **99.435**    **93.939**    **98.571**   **0.946**   **98.876**                  **96.875**                  **0.565**             **6.061**             **1.124**              **3.125**
  Without invariable dinucleotides   **99.107**    **93.939**    **97.931**   **0.941**   **98.230**                  **96.875**                  **0.893**             **6.061**             **1.770**              **3.125**
  **[Acceptor]{.ul}**                                                                                                                                                                                                
  **MES and SSF-like sequential**                                                                                                                                                                                    
  All variants                       91.579        **95.122**    **92.647**   **0.837**   **97.753**                  82.979                      8.421                 **4.878**             **2.247**              17.021
  Without invariable dinucleotides   71.429        **95.000**    **85.294**   **0.699**   **90.909**                  82.609                      28.571                **5.000**             **9.091**              17.391
  **SSF-like**                                                                                                                                                                                                       
  All variants                       **92.632**    92.683        **92.647**   0.832       96.703                      **84.444**                  **7.368**             7.317                 3.297                  **15.556**
  Without invariable dinucleotides   **75.000**    92.500        **85.294**   0.695       87.500                      **84.091**                  **25.000**            7.500                 12.500                 **15.909**

The best performance scores are highlighted in bold. The atypical

BRCA2

exon 17 native donor site (GC) was not estimated by HSF nor MES, and we have considered it as a failed prediction of the two tools for variants affecting this exon regardless of the

in vitro

splicing effect of the variant. False Discovery Rate represents the rate of false positives of the total of variants positively predicted and False Omission Rate represents the rate of false negatives of the total negative predicted variants.

![Prediction performance of HSF+SSF-like for donor sites and SSF-like for acceptor sites with variants collected in the **validation set.** Correct prediction: *in silico* and *in vitro* results are concordant. Incorrect prediction: *in silico* and *in vitro* results are discordant.](fgene-09-00366-g004){#F4}

The data analysis indicated that for 5′ donor sites the best combinations, with 98.57% accuracy, 99.44% of sensitivity and 96.88% of NPV, are HSF+SSF-like or HSF+SSF-like+MES (**Table [3](#T3){ref-type="table"}**) with very slight differences in performance, between the estimations of splicing effects for all variants (including variants placed at invariable dinucleotides) and for the group of variants located outside the two invariable nucleotides. For acceptor sites, the sequential combination of MES and SSF-like ([@B11]) and SSF-like stand-alone reached a performance with the same score of accuracy, 92.65%, but SSF-like showed a highest NPV (**Table [3](#T3){ref-type="table"}**). Unlike the donor site, the accuracy of these predictors decreased (to 85.29%) when the variants analyzed did not include those at the two nucleotide invariables (AG) of the 3′ acceptor splice site (**Table [3](#T3){ref-type="table"}**). For predictions of variants outside these dinucleotides, the rate of false negatives showed by SSF-like is slightly lower than those rates of MES and SSF-like sequential combination (25% versus 28.57%, respectively, **Table [3](#T3){ref-type="table"}**).

Discussion
==========

The use of massive parallel sequencing in clinical diagnostics is leading to a significant increase in data and the detection of a high number of variants of uncertain significance (VUS) with potential effect on splicing which need interpretation. Therefore, prediction of the effect of DNA sequence variations on splicing using *in silico* tools has become a common approach. Several studies have been published on the performance and reliability of *in silico* predictions of the splicing impact of variants ([@B14]). **Table [1](#T1){ref-type="table"}** details the results obtained in these studies and shows that the recommendations provided about the most appropriate to be used are not concordant. However, the studies that give clear recommendations, always include one of the HSF, SSF, or MES programs, alternatively.

We have evaluated the reliability of *in silico* splicing effect predictions of six programs (MES, HSF, SSF-like, SPANR, NNSplice, and dbscSNV) comparing their scores with splicing *in vitro* analysis outcomes of variants identified in hereditary cancer related genes. We elaborated the study in two stages, discovery and validation, to identify the best predictors or the best combination for their application in routine clinical testing, taking into account the percentages reached for sensitivity, specificity, accuracy and NPV as well as the score of Mathews Coefficient Correlation (MCC).

In the discovery stage, significant performance differences were appreciated among individual tools (**Table [2](#T2){ref-type="table"}**). For global, as well as for 5′, and 3′ splice sites, low accuracies of SPANR and NNSplice contrasted with the high performance achieved by SSF, MES, and HSF, while dbscSNV demonstrated an intermediate accuracy.

At the second stage of our study, we validated the combinations of HSF with SSF-like or HSF+SSF-like+MES as the highest performance for splicing aberrations at donor sites, and SSF-like stand-alone at acceptor sites (**Table [3](#T3){ref-type="table"}**). All these results are in agreement with the trend observed in the previous published results, where HSF or SSF or MES outperformed other methods (**Table [1](#T1){ref-type="table"}**). Of note, besides high accuracy and sensitivity, these validated tools, combined or as stand-alone, also had high NPV. This is relevant in a clinical setting, since it allows to separate the variants with an extremely low or non-existent probability of being abnormally spliceogenic from those variants in which *in vitro* RNA studies are of interest, with the consequent saving of resources in the laboratory.

All of the three predictors are available through Alamut Visual 2.10 (Interactive Biosoftware, Rouen), allowing a high throughput analysis, which is essential in a massive parallel sequencing annotation pipeline. Yet, in the newest version of Alamut Visual (2.11) the HSF predictor is not included in its splicing module, it is freely available at Human Splice Finder website^[3](#fn03){ref-type="fn"}^ or through VarAFT software^[4](#fn04){ref-type="fn"}^, which allows the annotation of a large batch of variants. MES program is also freely accessible via web^[5](#fn05){ref-type="fn"},[6](#fn06){ref-type="fn"}^, although caution should be taken when obtaining predictions via Alamut or via web, since differences have been reported ([@B25]). SSF-like tool is currently only accessible through Alamut, yet it has been recently published a free program named Splicing Prediction in Consensus Elements (SPiCE^[7](#fn07){ref-type="fn"}^) that combines predictions from SSF-like and MES ([@B16]). On the other hand, SPANR and dbscSNV are free and could be easily implemented in a pipeline ([@B30]; [@B17]), but these tools are not able to interpret splicing alterations caused by insertion or deletions (6.36% of validation set variants), which represents a limitation for their use compared to the other tools.

Non-canonical GC-AG and AT-AC sequences at the splice site invariant positions occur in 0.56 and 0.09% of the splice site pairs, respectively ([@B1]). In the list of the genes that we analyzed, only six splice sites vary from the canonical splice site GT-AG: *ATM* exon 50 donor site (GC), *BRCA2* exon 17 donor site (GC), *MUTYH* exon 14 donor site (GC), *PALB2* exon 12 donor site (GC), *STK11* exon 2 donor site (AT) and exon 3 acceptor site (AC). In our validation dataset, we only had variants at atypical *BRCA2* exon 17 donor site (GC), and among the studied tools, only SSF-like and SPANR were able to identify these atypical splicing sites and made a prediction for variants located nearby. As the performance of SSF-like is better than SPANR, we suggest the use of SSF-like to analyze these non-canonical splicing sites.

The tools analyzed in this article have only been interrogated to predict alteration at donor and acceptor splice sites. However, alterations in RNA may be produced by variant effects on other factors in *cis* (branch points, polypyrimidine tract, intronic and exonic splicing silencers and enhancers) or create new splice sites or activate cryptic ones. At the stage of validation, the rate of false negative predictions is significantly higher for acceptor sites than for donor sites (**Table [3](#T3){ref-type="table"}**). This difference may be due to the greater complexity of the sequence adjacent to the 3′, with the presence of the branch point and the polypyrimidine tract. Therefore, variants located in these two last elements could alter RNA and not be detected as changes in the scores of the splicing sites computed by the predictors. For example, the variant c.1066-6T\>G at *ATM* (included in the validation set), which is not predicted correctly by MES and SSF-like sequential combination (**Supplementary Table [7](#SM1){ref-type="supplementary-material"}**), alters the polypyrimidine tract causing an aberrant transcript ([@B7]).

Likewise, the *BRCA2* exonic variant c.467A\>G, located nine nucleotides upstream from the 5′ donor site, causes the loss of these last nine nucleotides, while the HSF and SSF-like predicts that their scores for the native donor splice site of 88.9 and 84.5, respectively, are not changed by the variant, which it is misinterpreted as a false negative (**Supplementary Table [6](#SM1){ref-type="supplementary-material"}**). Using some of the tools analyzed in our study to identify enhanced cryptic sites or creation of new splice sites, the variant is predicted to cause a new donor site at nine nucleotides from 5′, in concordance with *in vitro* results: SSF-like indicates a new donor site with a score of 96.9 against 84.5 of the natural splice site, MES 11.1 vs. 9.5 and HSF 98.2 vs. 88.9.

Furthermore, variants located in the exonic regions collected in our study could affect enhancer elements (ESEs) leading to an exon skipping, but they would not be correctly predicted by the analyzed tools. Although variants with specific experimental evidence of suffering this type of alteration were not included in our study, most articles consulted do not explicitly describe or exhaustively exclude the effect of ESEs. As an example, the *BRCA1* c.557C\>A altering splicing variant gathered at validation set is not predicted to affect native acceptor site by SSF-like, but specific tools to predict splicing defect caused by regulatory sequence disruption indicates an ESE disturbance: ESRseq score of -1.567 ([@B15]) and HEXplorer ΔHZ~EI~ = -30.24 ([@B9]).

Computational tools or programs able to perform predictions on the disruption of all *cis* DNA elements would cover the whole landscape of aberrant RNA splicing yielded by spliceogenic VUS. Theoretically, SPANR is able to detect exon skipping caused by all of the elements above mentioned, although our study indicated that this program has a low performance for at least to predict correctly alterations of donor and acceptor sites (**Table [2](#T2){ref-type="table"}**). The HSF predictor accessed via its website^[8](#fn08){ref-type="fn"}^, also predicts the impact of genetic variations on branch point elements and has been improved for the identification of natural non-canonical splice sites ([@B19]). The breast cancer genes PRIORS probabilities program^[9](#fn09){ref-type="fn"}^, gives MES estimations of disruption of natural splice sites and also computes the creation of new donor and acceptor splice sites using NNSplice, yet only for *BRCA1* and *BRCA2* genes ([@B27]). However, the accuracy and performance of SPANR, HSF, and PRIORS predictions of variants placed in elements other than natural splice sites has not yet been evaluated.

To our knowledge, our study is the only that evaluates the accuracy of different tools separately for donor and acceptor sites, resulting in different recommendations for each one with high performance (**Table [1](#T1){ref-type="table"}**).

One limitation of our study is the use of splicing *in silico* tools through a non-free commercial program, Alamut Visual 2.10, with the uncertainty of whether the predictions obtained through Visual Alamut are the same as those estimated directly by the tools in their respective free access websites. We have confirmed that HSF via web (see footnote 8; data not shown) and MES via SPICE (see footnote 7; **Supplementary Table [8](#SM1){ref-type="supplementary-material"}**), at least for native splice sites, provide the same estimations than those provided by Alamut Visual 2.10. However, SSF-like predictions obtained through Alamut Visual 2.10 slightly differ from the predictions ascertained through SPICE (**Supplementary Table [8](#SM1){ref-type="supplementary-material"}**). Therefore and considering our findings, we recommend as a free pipeline to use HSF accessed via web and MES via SPICE for donor and acceptor site predictions, respectively.

Another limitation is the higher number of variants causing splicing defects compared to the number of variants causing no splicing alteration in our validation dataset. This bias is due to a tendency to report only variants that cause splicing defects. Some studies, in order to avoid this bias, have included common single nucleotide polymorphisms (SNPs) from control dataset, assuming that they do not cause alterations (**Table [1](#T1){ref-type="table"}**). Likewise, reports of RNA *in vitro* effects of variants in the two invariable dinucleotides GT-AG are overrepresented, while those located further from splice junctions are less frequently analyzed.

Conclusion
==========

In conclusion, to perform *in silico* analysis of VUS potentially affecting natural splice sites in hereditary cancer genes, we recommend the use of the HSF+SSF-like combination (with Δ-2% and Δ-5% as thresholds, respectively) for donor sites and SSF-like (Δ-5%) stand-alone for acceptor sites. These tools have shown in the validation stage a high sensitivity and especially a high NPV. Although the *in vitro* study of RNA remains the gold standard to evaluate the process of splicing, and it is not recommended to use these predictions as the sole source of evidence to make clinical assertions ([@B22]), our results indicate that these combined tools can be used to filter out VUS with a very low probability of altering splicing without losing true spliceogenic variants that will need deeper experimental validation. Complementing the analysis using specific predictors to identify variants that could affect elements other than splice sites (such as branch points or ESEs), may be useful for the screening of the whole RNA defect landscape. Lastly, it is worth stating that (i) the aim of this work was not to classify variants but to provide an *in silico* algorithm with the highest performance to predict an altered *in vitro* splicing regardless of whether the variants are benign or pathogenic; and (ii) the detection of splicing defect does not automatically denote the pathogenicity of the variant for which a comprehensive qualitative and quantitative RNA analysis is warranted as highlighted in ENIGMA^[10](#fn10){ref-type="fn"}^ or ACGM guidelines ([@B22]) for variant classification.
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